Our team of pediatric specialists works with families to achieve outcomes that are among the best when compared to other high-volume IBD programs in the United States. The comprehensive care we provide includes:

  • Sophisticated diagnostic testing
  • Ongoing therapy for IBD and its side effects
  • Consultations and second opinions for complex cases
  • Surgical treatment, if needed 
  • Patient education to help children and teens learn to manage their condition 


In 2007 Cincinnati Children’s helped establish ImproveCareNow, a quality improvement and learning network for pediatric inflammatory bowel disease providers and researchers, as well as patients and families. Our physicians continue to provide leadership within the network, which now includes more than 105 member institutions in the United States and internationally. Participating care providers and researchers analyze results from thousands of doctor/patient visits and review the latest IBD studies and treatments worldwide. As we share this information, we continue to improve care for all patients. Since ImproveCareNow was established, remission rates at all member hospitals have improved significantly.

Current Clinical Trials

Telehealth Enhancement of Adherence to Medication in Pediatric IBD:  The TEAM Study
This multicenter randomized controlled trial will test the efficacy of a telehealth behavioral treatment on medication adherence in children and adolescents with IBD.

A Randomized, Double-Blind, Placebo-controlled, Multi-center Pragmatic Clinical Trial to Evaluate the Effectiveness of Low Dose Oral Methotrexate in Patients with Pediatric Crohn’s Disease Initiating Anti-TNF Therapy: The COMBINE Study
This multicenter randomized controlled trial will determine whether the addition of low dose methotrexate to anti-TNF therapy results in better outcomes for children with Crohn’s Disease.

Dosing and Pilot Efficacy of 2'-Fucosyllactose in Inflammatory Bowel Disease
The major goals of this study are to determine whether dietary supplementation with the 2'-Fucosyllactose prebiotic in IBD will be safe and well tolerated, while increasing levels of beneficial gut bacteria in a dose dependent manner.